XLO - Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting | Benzinga
WALTHAM, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced upcoming poster presentations at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, taking place in San Diego, California from November 1-5, 2023. The company plans to present preliminary anti-tumor activity, safety, pharmacokinetic and pharmacodynamic data from its Phase 1/2 clinical trial for XTX202, a tumor-activated, engineered, beta-gamma biased IL-2, as well as preclinical data for XTX301, a tumor-activated, engineered IL-12.
Poster presentation details:
- Title: Phase 1/2 First-in-Human Study of XTX202, a Masked, Tumor-Activated IL-2??, in Patients with Advanced Solid Tumors: Results from Phase 1
- Presentation Date: Friday, November 3, 2023, 9:00 am to 7:00 pm PDT
- Abstract Number: 611
- Location: Exhibit Halls A and B1
- Title: XTX301, a Tumor Activated, Half-Life Extended IL-12, Promoted Potent Anti-Tumor Immunity and Activity Across Multiple Syngeneic Tumor Models
- Presentation Date: Saturday, November 4, 2023, 9:00 am to 7:00 pm PDT
- Abstract Number: 1056
- Location: Exhibit Halls A and B1
About Xilio Therapeutics
Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary geographically precise solutions (GPS) platform to build a pipeline of novel, tumor-activated molecules, including antibodies, cytokines and other biologics, which are designed to optimize their therapeutic index and localize anti-tumor activity within the tumor microenvironment. ...